Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 1205 • 2015 ACR/ARHP Annual Meeting
The Spectrum of Early RA Practice Across the Globe: Results from a Multinational Cross Sectional Survey
Elena Nikiphorou¹, James Galloway^2,3, Piet L van Riel⁴, Andrew Östör⁵, Glenn Haugeberg^6,7, Feride Gogus^8,9, Markku Kauppi¹⁰, Yusuf Yazici¹¹ and Tuulikki Sokka-Isler¹², ¹Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Academic Department of Rheumatology, King´s College London, London, United Kingdom, ³King's College Hospital, Department of Rheumatology, London, London, United Kingdom, ⁴Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, Netherlands, ⁵Addenbrooke's Hospital, Cambridge, United Kingdom, ⁶Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway, ⁷Head of the Department of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁸University of Gazi, Ankara, Turkey, ⁹Gazi University, Faculty of Medicine, Ankara, Turkey, ¹⁰Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ¹¹Rheumatology, Hospital for Joint Diseases and Medicine, NYU Langone Medical Centre, New York, NY, ¹²Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Early diagnosis & treatment are crucial to the management of rheumatoid arthritis (RA). Despite this, the approach to early RA management appears to be…
Abstract Number: 2695 • 2015 ACR/ARHP Annual Meeting
Th17 Cell Related Cytokines and Microarray Expression Profiles in Patients with Early Rheumatoid Arthritis
Youngkyun Kim¹, Kijun Lee², Hae-Rim Kim³, Sang Heon Lee⁴, Ji Hyeon Ju⁵ and HO-YOUN KIM⁶, ¹1Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea, Seoul, South Korea, ²The Catholic University of Korea, Seoul, South Korea, ³Konkuk University Medical Center, Seoul, South Korea, ⁴Konkuk University Hospital, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶Konkuk university hospital, Seoul, South Korea
Background/Purpose: The purpose of this study is to explore new biomarkers for early diagnosis of rheumatoid arthritis (RA). For better discrimination power, we especially investigated…
Abstract Number: 503 • 2015 ACR/ARHP Annual Meeting
Predictors for Attaining Remission at Two Consecutive Visits in Newly Diagnosed Early RA Patients
T. Martijn Kuijper¹, J.J. Luime², P.H.P. de Jong³, A. H. Gerards⁴, Derkjen van Zeben⁵, I. Tchetverikov⁶, P.B.J. de Sonnaville⁷, M. van Krugten⁸, B. Grillet⁹, Mieke Hazes¹⁰ and A.E.A.M. Weel^11,12, ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ³Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁶Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ⁷Oosterschelde Hospital, Goes, Netherlands, ⁸Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands, ⁹Rheumatology, ZorgSaam Hospital, Terneuzen, Netherlands, ¹⁰Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, ¹¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ¹²Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands
Background/Purpose: Early and intensive treatment with DMARDs are essential for remission induction in newly diagnosed RA patients. However, demographic, psychosocial and disease related factors may…
Abstract Number: 1325 • 2015 ACR/ARHP Annual Meeting
Age Effects Joint Space Narrowing in Early Active Rheumatoid Arthritis Patients
Xanthe M.E. Matthijssen¹, Gülsah Akdemir¹, Iris M. Markusse², Yvonne P. Goekoop-Ruiterman³, K. Huub Han⁴, Annekoos L. Huidekoper⁵, Pit J.S.M. Kerstens⁶, Willem F. Lems⁷, T. W. J. Huizinga¹ and Cornelia F. Allaart¹, ¹Rheumatology, LUMC, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Rheumatology, Maasstad hospital, Rotterdam, Netherlands, ⁵Rheumatology, Bronovo hospital, The Hague, Netherlands, ⁶Department of Rheumatology, Reade, Amsterdam, Netherlands, ⁷Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Joint space narrowing (JSN) and erosions are the major radiologic markers of radiographic progression in rheumatoid arthritis (RA), as scored by the Sharp/van der…
Abstract Number: 2721 • 2015 ACR/ARHP Annual Meeting
Elevated Subgingival Levels of Periodontal Pathogens in Rheumatoid Arthritis Patients, Particularly Leptotrichia species in New-Onset Disease
Sheila Arvikar¹, Hatice Hasturk², Daniel Nguyen², Klemen Strle³, Marcy B. Bolster⁴, Deborah Collier⁵, Allen C. Steere⁶ and Alpdogan Kantarci², ¹Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Applied Oral Health Sciences, Forsyth, Cambridge, MA, ³Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Periodontitis, a polymicrobial infectious and inflammatory disease of tooth-supporting structures, shares pathogenic mechanisms with rheumatoid arthritis (RA) and may trigger its onset. Most studies…
Abstract Number: 514 • 2015 ACR/ARHP Annual Meeting
MRI Bone Oedema at Enrollment Predicts the Development of Rapid Radiographic Progression at 1 Year Toward Patients with Early-Stage Rheumatoid Arthritis: Results from Nagasaki University Early Arthritis Cohort
Yoshikazu Nakashima¹, Mami Tamai², Toru Michitsuji³, Toshimasa Shimizu², Shoichi Fukui⁴, Masataka Umeda¹, Ayako Nishino¹, Tomohiro Koga³, Shin-ya Kawashiri⁵, Naoki Iwamoto², Kunihiro Ichinose², Yasuko Hirai⁴, Hideki Nakamura⁴, Tomoki Origuchi⁶ and Atsushi Kawakami⁴, ¹Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ⁴Nagasaki University, Nagasaki, Japan, ⁵Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, ⁶Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan
Background/Purpose: To clarify whether MRI bone oedema predicts the development of rapid radiographic progression (RRP) in Nagasaki University Early Arthritis Cohort patients with early-stage rheumatoid…
Abstract Number: 1636 • 2015 ACR/ARHP Annual Meeting
Clinical Benefit of 1-Year Certolizumab Pegol Treatment in MTX-Naïve, Early Rheumatoid Arthritis Patients Is Maintained after Discontinuation up to 1 Year
Tatsuya Atsumi¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Osamu Togo¹¹, Toshiyuki Okada¹², Désirée van der Heijde¹³, Nobuyuki Miyasaka¹⁴ and Takao Koike¹⁵, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ¹⁰Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, ¹¹Biometrics Group, UCB Pharma, Tokyo, Japan, ¹²Astellas Pharma Inc., Japan, Tokyo, Japan, ¹³University Hospital, Maastricht, Netherlands, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Efficacy and safety of certolizumab pegol (CZP) treatment in combination with optimized-dose MTX in Japanese MTX-naïve early rheumatoid arthritis (RA) patients (pts) with poor…
Abstract Number: 2736 • 2015 ACR/ARHP Annual Meeting
Reduction of Disease Burden on Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in DMARD-Naïve Patients with Active, Severe, Progressive Rheumatoid Arthritis
VP Bykerk¹, Clifton Bingham², Gerd Burmester³, Daniel E. Furst⁴, Xavier Mariette⁵, Oana Purcaru⁶, Brenda VanLunen⁷, Michael Weinblatt⁸ and Paul Emery⁹, ¹Hospital for Special Surgery, New York, NY, ²Johns Hopkins University, Baltimore, MD, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ⁶Outcomes & Access Immunology, UCB, Brussels, Belgium, ⁷UCB Pharma, Raleigh, NC, ⁸Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ⁹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is associated with work disability and lower employment rates (evidence shows 20–30% of pts are work disabled in the first 3…
Abstract Number: 519 • 2015 ACR/ARHP Annual Meeting
In Indigenous North Americans at High Risk for RA Complement C5 Level Is Associated with ACPA Positivity and C5a with Transition to Synovitis Even after Correcting for in Vitro Complement Activation Found with Prolonged Sample Storage
Ceri Richards¹, Carol Hitchon², Xiaobo Meng³, Irene Smolik⁴, David Robinson⁴ and Hani S. El-Gabalawy⁴, ¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³University of Manitoba, Winnipeg, MB, Canada, ⁴Arthritis Center, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Complement activation, a key component of innate immunity and activator of adaptive immunity has been linked to RA pathogenesis. Anti-citrullinated peptide antibody (ACPA) and…
Abstract Number: 1638 • 2015 ACR/ARHP Annual Meeting
Early Response As a Predictor of Long-Term Remission in DMARD-Naïve Patients with Severe, Active and Progressive Rheumatoid Arthritis Treated with Certolizumab Pegol in Combination with Methotrexate
Michael Weinblatt¹, Clifton Bingham², Gerd Burmester³, VP Bykerk⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Désirée van der Heijde⁷, Daljit Tatla⁸, Catherine Arendt⁹, Irina Mountian¹⁰, Brenda VanLunen¹¹ and Paul Emery¹², ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Hospital for Special Surgery, New York, NY, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ⁷University Hospital, Maastricht, Netherlands, ⁸8010 Arco Corporate Dr, UCB Pharma, Raleigh, NC, ⁹Global Medical Affairs, UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: In established rheumatoid arthritis (RA), a lack of response to treatment with certolizumab pegol (CZP) at early timepoints is associated with a low probability…
Abstract Number: 2741 • 2015 ACR/ARHP Annual Meeting
An Analysis of the Efficacy of Tofacitinib Monotherapy in MTX-Naïve Patients with Early RA Compared with Patients with Established RA
Roy Fleischmann¹, T. W. J. Huizinga², Arthur Kavanaugh³, Bethanie Wilkinson⁴, Kenneth Kwok⁵, Ryan DeMasi⁵ and Ronald F. van Vollenhoven⁶, ¹Metroplex Clinical Research Center, Dallas, TX, ²Leiden University Medical Center, Leiden, Netherlands, ³University of California, San Diego School of Medicine, LaJolla, CA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. In a Phase 3 study (ORAL Start; NCT01039688), tofacitinib monotherapy in MTX-naïve…
Abstract Number: 539 • 2015 ACR/ARHP Annual Meeting
Quantification of T-Cell Receptor Excision Circles (TREC) from Peripheral Blood in Patients with Inflammatory Polyarthritis of Recent Onset (EPA): Association with Radiographic Joint Damage
Alexandre Osborne¹, Nathalie Carrier², Artur J de Brum-Fernandes³, Patrick Liang³, Ariel Masetto⁴ and Gilles Boire³, ¹Clinical Sciences Program, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Patients with established Rheumatoid arthritis (RA) present evidence for an exhausted immune system. It is not known whether patients seen at the Early inflammatory…
Abstract Number: 1644 • 2015 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data 3 (RAPID3)-Defined Remission Is As Stringent As ACR/EULAR Boolean-Defined Remission in a Clinical Trial of Patients with Early Rheumatoid Arthritis Treated with Abatacept
Yusuf Yazici¹, KK Gandhi², E Alemao² and Daniel E. Furst³, ¹NYU Hospital for Joint Diseases, New York, NY, ²Bristol-Myers Squibb, Princeton, NJ, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Routine Assessment of Patient Index Data 3 (RAPID3) comprises the three patient-reported ACR RA Core Data Set measures: function (HAQ-DI), pain and patient global…
Abstract Number: 2748 • 2015 ACR/ARHP Annual Meeting
Evaluation of Patient-Reported Outcomes By Baseline Disease Duration: 6-Month Data from Two Clinical Trials of Patients with Early Rheumatoid Arthritis Treated with Abatacept
Daniel E. Furst¹, VP Bykerk², Gerd Burmester³, BG Combe⁴, T. W. J. Huizinga⁵, E Alemao⁶, A Johnsen⁶ and Paul Emery⁷, ¹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Weill Cornell Medical College, New York, NY, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Montpellier University, Montpellier, France, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Patients with RA and longer disease duration generally do not respond as well to treatment with DMARDs as patients with shorter duration of disease.…
Abstract Number: 541 • 2015 ACR/ARHP Annual Meeting
Microrna-125b Expression in PBMCs Is Associated with Disease Activity in Patients with Early Rheumatoid Arthritis
Veronika Hruskova^1,2, Romana Jandová³, Lucia Vernerova⁴, Herman F Mann⁵, Klára Prajzlerová⁴, Maria Filkova⁴, Karel Pavelka⁵, Jiri Vencovsky⁵ and Ladislav Senolt⁵, ¹Institute of Rheumatology and Department of Rheumatology; Faculty of Science Charles University, Prague, Czech Republic, ²Faculty of Science, Charles University, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: MicroRNAs (miRNAs) are small non-coding RNAs that function as negative regulators of gene expression at posttranscription level and play a significant role in rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].